REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders
Psychiatry and Clinical Neurosciences · 2025
DOI: 10.1111/pcn.13800 ↗At a glance
Klinische Studie (Phase II) in Psychiatry and Clinical Neurosciences, 2025. Written by Marc Ferrer and 9 co-authors. Institution: Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Major MEDLINE topics: Aggression, Borderline Personality Disorder, Attention Deficit Disorder with Hyperactivity, Autism Spectrum Disorder. Cited 6 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0). Funded by: Oryzon Genomics SA.
Topics: Gewalt gegen Pflegekräfte
Abstract (original language)
Aim
Vafidemstat is a brain‐penetrant, orally bioavailable, small molecule irreversible inhibitor of the histone lysine‐specific demethylase KDM1A (also known as LSD1), which corrects memory deficits and behavior alterations including aggression and social interaction deficits in preclinical models.
Methods
Here, we report the results of REIMAGINE, a phase IIa, single‐center, open‐label, one‐arm basket trial that evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention‐deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD). Participants received 1.2 mg/day of vafidemstat for 8 weeks.
Results
Vafidemstat was shown to be safe and well tolerated, and no drug‐related clinically significant adverse events were observed. Furthermore, all neuropsychiatric scales assessed showed notable efficacy signals, whether assessing agitation/aggression (Clinical Global Impression for Severity [CGI‐S] and Clinical Global Impression for Improvement [CGI‐I] and Neuropsychiatric Inventory [NPI] questionnaire for Agitation‐Aggression [NPI‐AA]), overall patient functioning (total NPI), or disease‐specific features (Attention‐Deficit/Hyperactivity Disorder Rating Scale [ADHD‐RS] and Borderline Personality Disorder Checklist [BPDCL]). Statistically significant improvements were observed in the aggregated data (all participants) and for each of the three disease groups independently. Changes were evident within the first 2 weeks of treatment.
Conclusion
In summary, the REIMAGINE study supports that vafidemstat is safe, well tolerated, and causes a significant and consistent reduction in agitation/aggression and nonaggression features in BPD, ADHD, and ASD. These data support continuing the development of vafidemstat as a new treatment option for these psychiatric disorders.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Oryzon Genomics S.A. Cornellà de Llobregat, Barcelona, Spain.
ORCID profiles: Jordi Xaus
Funding
- Oryzon Genomics SA
Cite
APA
Ferrer, M., Richarte, V., Gisbert, L., Xaus, J., Gutierrez, S., Arevalo, M. I., Ropacki, M., Bullock, R., Buesa, C., & Ramos-Quiroga, J. A. (2025). REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13800
Vancouver
Ferrer M, Richarte V, Gisbert L, Xaus J, Gutierrez S, Arevalo MI, et al. REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13800
BibTeX
@article{Ferrer2025,
author = {Ferrer, Marc and Richarte, Vanesa and Gisbert, Laura and Xaus, Jordi and Gutierrez, Sonia and Arevalo, Maria Isabel and Ropacki, Michael and Bullock, Roger and Buesa, Carlos and Ramos-Quiroga, Josep Antoni},
title = {REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders},
journal = {Psychiatry and Clinical Neurosciences},
year = {2025},
doi = {10.1111/pcn.13800}
}
EUVIMED